Akari Therapeutics to Present at Virtual Investor Closing Bell Series on September 4th

Akari Therapeutics will participate in the Virtual Investor Closing Bell Series on September 4, 2025. Abizer Gaslightwala, President and CEO, will provide a corporate overview and discuss the company's innovative payload platform for next-generation ADCs. Investors can submit questions live during the event, and a webcast replay will be available on the company's website.

Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, will participate in the Virtual Investor Closing Bell Series on September 4, 2025, at 4:00 PM ET. During the event, CEO Abizer Gaslightwala will present a corporate overview, focusing on the company's innovative payload platform for developing next-generation antibody drug conjugates (ADCs) in cancer treatment [1].

The event will feature a moderated discussion followed by a live Q&A session with investors. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days after the event [1].

Gaslightwala will discuss the company's unique payload platform, which is designed to disrupt RNA splicing within cells using PH1, a novel spliceosome modulator. This mechanism of action differentiates PH1 from traditional ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. Preclinical studies have shown that PH1 induces cancer cell death while activating immune cells to drive robust and durable activity [1].

Akari Therapeutics' lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor. Preclinical studies have demonstrated that AKTX-101 has significant activity and prolonged survival compared to ADCs with traditional payloads. Additionally, AKTX-101 has shown potential synergy with checkpoint inhibitors and prolonged survival as both a single agent and in combination with checkpoint inhibitors [1].

Investors and interested parties are encouraged to submit questions live during the event. The live video webcast will be available in the Investors section of the Company’s website (akaritx.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days [1].

For more information about the company, please visit www.akaritx.com and connect on X and LinkedIn.

References:
[1] https://www.stocktitan.net/news/AKTX/akari-therapeutics-to-participate-in-the-virtual-investor-closing-je5bz8o5tp24.html
[2] https://www.morningstar.com/news/globe-newswire/9521998/akari-therapeutics-to-participate-in-the-virtual-investor-closing-bell-series